These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 12745087)

  • 1. [2-Sulfo-9-fluorenylmethoxycarbonyl]3-exendin-4-a long-acting glucose-lowering prodrug.
    Shechter Y; Tsubery H; Fridkin M
    Biochem Biophys Res Commun; 2003 May; 305(2):386-91. PubMed ID: 12745087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl](3)-insulin.
    Gershonov E; Goldwaser I; Fridkin M; Shechter Y
    J Med Chem; 2000 Jun; 43(13):2530-7. PubMed ID: 10891112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.
    Sasson K; Marcus Y; Lev-Goldman V; Rubinraut S; Fridkin M; Shechter Y
    J Control Release; 2010 Mar; 142(2):214-20. PubMed ID: 19883707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-[(2-Sulfo)-9-fluorenylmethoxycarbonyl](3)-gentamicin C(1) is a long-acting prodrug derivative.
    Shechter Y; Tsubery H; Fridkin M
    J Med Chem; 2002 Sep; 45(19):4264-70. PubMed ID: 12213067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible pegylation of insulin facilitates its prolonged action in vivo.
    Shechter Y; Mironchik M; Rubinraut S; Tsubery H; Sasson K; Marcus Y; Fridkin M
    Eur J Pharm Biopharm; 2008 Sep; 70(1):19-28. PubMed ID: 18495444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).
    Park EJ; Lim SM; Lee KC; Na DH
    Expert Opin Ther Pat; 2016 Jul; 26(7):833-42. PubMed ID: 27196800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
    Shechter Y; Preciado-Patt L; Schreiber G; Fridkin M
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1212-7. PubMed ID: 11158619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering a novel protease-based Exendin-4 derivative for type 2 antidiabetic therapeutics.
    Zhong X; Yang S; Liu T; Ji S; Hu J; Li H
    Eur J Med Chem; 2018 Apr; 150():841-850. PubMed ID: 29597167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly designed modifier prolongs the action of short-lived peptides and proteins by allowing their binding to serum albumin.
    Shechter Y; Sasson K; Lev-Goldman V; Rubinraut S; Rubinstein M; Fridkin M
    Bioconjug Chem; 2012 Aug; 23(8):1577-86. PubMed ID: 22759320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification.
    Tsubery H; Mironchik M; Fridkin M; Shechter Y
    J Biol Chem; 2004 Sep; 279(37):38118-24. PubMed ID: 15190059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
    Ueda T; Ito T; Tomita K; Togame H; Fumoto M; Asakura K; Oshima T; Nishimura S; Hanasaki K
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4631-4. PubMed ID: 20576431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan.
    Ahn S; Lee IH; Lee E; Kim H; Kim YC; Jon S
    J Control Release; 2013 Sep; 170(2):226-32. PubMed ID: 23747732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Peptides; 2018 Feb; 100():202-211. PubMed ID: 29412820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of the glucagon-like peptide-1 analog exenatide extended-release in healthy cats.
    Rudinsky AJ; Adin CA; Borin-Crivellenti S; Rajala-Schultz P; Hall MJ; Gilor C
    Domest Anim Endocrinol; 2015 Apr; 51():78-85. PubMed ID: 25594949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas.
    Gezginci-Oktayoglu S; Bolkent S
    Biochem Cell Biol; 2009 Aug; 87(4):641-51. PubMed ID: 19767827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
    Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M
    J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.